Core Viewpoint - Dongyang Sunshine Pharmaceutical (06887) saw a stock price increase of over 4%, closing at HKD 47.7, following the approval of its Fingo Mod capsule for market launch in China, marking it as the first domestic generic and the company's first oral immunosuppressant [1][1][1] Company Summary - The approval of Fingo Mod, the first oral medication for multiple sclerosis (MS), was announced by the National Medical Products Administration of China on October 11 [1][1] - Fingo Mod was developed by Novartis and Mitsubishi Tanabe Pharma, achieving global sales exceeding USD 3 billion annually from 2016 to 2020 [1][1] - Dongyang Sunshine Pharmaceutical is recognized as the first company in China to utilize a merger and acquisition strategy for its public listing, establishing an integrated platform for research, production, and sales of innovative drugs [1][1] Industry Summary - The research report from China Merchants Securities highlights the company's focus on three main research areas: anti-infection, chronic diseases (metabolism), and oncology, indicating a rich pipeline of research and development [1][1] - The company’s products are rapidly gaining market traction, signaling the beginning of a new chapter in global innovation [1][1] - The report provides a strong recommendation for investment, reflecting confidence in the company's innovative pipeline development [1][1]